Why we evaluate
External evaluations are an essential component of our approach to performance management and monitoring, transparency and accountability, and communicating results and learning.
External evaluations are one of several approaches that we apply to ensure effective performance to deliver global health impact. Other approaches include regular internal monitoring, external audits, partner engagement, and external verifications. External evaluations provide us with an independent assessment of the results delivered through our investments, input for course correction and a consolidation of lessons learned and recommendations to inform future investments.
How we approach evaluation
Unitaid requires at least one evaluation over the course of each grant. We typically commission external end-of-grant evaluations within 12 months before or after grant closure. Unitaid may decide to conduct prospective evaluations to provide an ongoing assessment over the course of implementation to facilitate real-time learning and course correction. In addition, we may commission thematic evaluations to review performance and capture learning within cross-cutting areas of our strategic framework or specific technical areas/ approaches.
External evaluations are contracted, funded and managed by Unitaid. We select evaluators through an open, competitive procurement process that follows best practice, with clear terms of reference outlining required experience and expertise. To promote efficient use of resources, we prioritize selection of evaluators with a presence in the region/countries of implementation and ensure evaluators make use of existing data, research and findings of previously completed evaluations.
Our evaluation framework
Our approach to evaluation is guided by our evaluation framework. This framework is based on the internationally accepted evaluation framework of the Organisation for Economic Co-operation and Development (OECD) Development Assistance Committee (DAC), including its principles and criteria for grant evaluations.
The evaluation framework was updated in November 2022 to align with our 2023-2027 strategy.
We use this framework as the basis to develop the terms of reference that outlines the purpose and scope of work for a specific evaluation. Evaluation questions are prioritized and tailored according to the focus of the evaluation and the information needs. Appropriate data sources and methods are then defined to respond to each evaluation question.
Unitaid’s evaluation framework and additional guidance for implementers and evaluators is available here.
How we share and use evaluation findings
We disseminate evaluation findings and learning widely among our stakeholders and partners. Final reports are posted on our website (see below).
Evaluations are used to inform annual reporting on our strategic key performance indicators (KPIs), to support the ongoing performance management of our active portfolio and to inform the design of future investments.
- Currently there are no upcoming evaluations.
- New Nets Project: End of Project Evaluation.
- Antiretroviral Therapy (ART) Optimization, CHAI, Institut Bouisson Bertrand (IBB), University of Liverpool, University of New South Wales On behalf of Kirby Institute, Wits Reproductive Health (Wits RHI) on behalf of Ezintsha, Portfolio-Level End-of-Grant Evaluation.
- Supporting the use of TRIPS Flexibilities joint portfolio End-of-Project Evaluation.
Recently completed evaluations:
- Unitaid investment in Pre-Exposure Prophylaxis (PrEP), Wits Reproductive Health and HIV Institute (Wits RHI) and Fiotec, Joint Portfolio Level End-of-Project Evaluation, Final Report, 18 January 2023
- Unitaid investment in Pre-Exposure Prophylaxis (PrEP), Wits Reproductive Health and HIV Institute (Wits RHI) and Fiotec, Joint Portfolio Level End-of-Project Evaluation, Executive Summary, 18 January 2023
- Supporting the use of TRIPS Flexibilities, Joint Portfolio End-of-grant evaluation, 9 December 2022
- Transforming IPT for Optimal Pregnancy (TIPTOP) Project and Output 1 of the Supply Side Grant, Jhpiego, End-of-Grant Evaluation, Full Report, 11 August 2021
- Transforming IPT for Optimal Pregnancy (TIPTOP) & the Supply Side Grant, Jhpiego, Evaluation Summary, June 2022
- Unitaid HIV Self Testing (HIVST) area for intervention, Joint End-of-Project Evaluation, Final Report, 10 June 2022
- Unitaid HIV Self Testing (HIVST) area for intervention, Joint End-of-Project Evaluation, Supplementary Appendices, 10 June 2022
- Joint end of project evaluation – HIV Self-Testing (HIVST) area for intervention, Executive Summary, 10 June 2022
- Unitaid investment in Scale-up of Better TB Treatment in Children, EGPAF and University of Bordeaux, Joint Portfolio Level, End-of-Project Evaluation, August 2022
- Evaluation of Unitaid’s portfolio of COVID-19 Investments, Mid-term Evaluation, April 2022
- Evaluation of Unitaid’s portfolio of COVID-19 Investments, Supporting Appendices, Mid-term Evaluation, April 2022
- Unitaid 2017-2021 Strategy Review, Final Report/Main report, Vol 1
- Unitaid 2017-2021 Strategy Review, Final Report/Annexes, Vol 2
- Unitaid 2017-2021 Strategy Review, Management Response, December 2021
- The Medicines Patent Pool, End-of-Project Evaluation, Medicines Patent Pool, September 2021
- HIV Molecular diagnostics joint evaluation, Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Clinton Health Access Initiative (CHAI), and UNICEF, Joint Portfolio Level End-of-Project Evaluation, July 2021
- Unitaid investments in Hepatitis C, Foundation for Innovative New Diagnostics (FIND) and Coalition PLUS, Joint Portfolio Level Evaluation and End-of-Project Evaluations, June 2021
- HIV Self-Testing AfRica (STAR) Initiative, Population Services International (PSI) & Society for Family Health (SFH) – South Africa, Phase 2, End-of-Project Evaluation, May 2021
- Evaluation of CHAI Community access to rectal artesunate for malaria (CARAMAL) and Medicines for Malaria Venture (MMV) Supply Side Grant, May 2021
- Investing in insecticides to fight malaria (NgenIRS project), Innovative Vector Control Consortium, End-of-Project Evaluation, September 2020
- Providing access to viral-load monitoring and early-infant diagnosis by SAMBA, Diagnostics for the Real World, End-of-Project Evaluation, November 2019
- Better HIV treatment for infants and young children, Drugs for Neglected Diseases Initiative (DNDi), End-of-Project Evaluation, April 2019
- Improving access to diagnosis and treatment for hepatitis C in low- and middle-income countries, Médecins Sans Frontières, End-of-Project Evaluation, February 2019
- Generating demand for hepatitis C treatment, Coalition PLUS, Mid-term evaluation, October 2018
- Innovation in paediatric market access (IPMA), Clinton Health Access Initiative (CHAI), End-of-Project Evaluation, November 2018
- Sustainable quality control of rapid diagnostic tests for malaria, Foundation for Innovative New Diagnostics (FIND), End-of-Project Evaluation, June 2018
- Expanding HIV self-testing in Africa (Star Phase 1), Population Services International (PSI), Mid-term Evaluation, March 2018
- TBXpert: Innovative diagnostics for multidrug-resistant tuberculosis (MDR-TB), Global TB Programme, End-of-Project Evaluation, July 2017
- Seasonal malaria chemoprevention for children in the Sahel (ACCESS-SMC), Malaria Consortium, Mid-term Evaluation, July 2017
- Addressing neglected childhood tuberculosis (STEP-TB), TB Alliance, End-of-Project Evaluation, July 2017
- Better treatment for severe malaria, Medicines for Malaria Venture (MMV), End-of-Project Evaluation, March 2017
- WHO prequalification for diagnostics and medicines, World Health Organization (WHO), Mid-term Evaluation, June 2016
- Evaluation of OPP-ERA project (phase 2), France Expertise International, End-of-Project Evaluations, January 2015
- Click here to find older evaluations